COCP - Cocrystal Pharma, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Bothell,
United States
Type: Equity
COCP price evolution
COCP
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $18.25 | $21.96 | $26.47 | |
| Short term investments | ||||
| Net receivables | $0.65 | $1.08 | $1 | $0.89 |
| Inventory | ||||
| Total current assets | $14.26 | $19.66 | $24.49 | $29.09 |
| Long term investments | ||||
| Property, plant & equipment | $1.95 | $1.88 | $2.01 | $2.12 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.91 | $2.05 | $2.17 | |
| Total investments | ||||
| Total assets | $16.23 | $21.57 | $26.55 | $31.26 |
| Current liabilities | ||||
| Accounts payable | $0.86 | $1.74 | $2.14 | $3.02 |
| Deferred revenue | ||||
| Short long term debt | $0.25 | $0.24 | $0.24 | |
| Total current liabilities | $1.95 | $2.65 | $2.38 | $3.26 |
| Long term debt | $1.53 | $1.58 | $1.61 | |
| Total noncurrent liabilities | $1.53 | $1.58 | $1.61 | |
| Total debt | $1.78 | $1.82 | $1.85 | |
| Total liabilities | $3.53 | $4.18 | $3.96 | $4.88 |
| Shareholders' equity | ||||
| Retained earnings | -$330.15 | -$325.21 | -$319.87 | -$315.91 |
| Other shareholder equity | ||||
| Total shareholder equity | $17.39 | $22.59 | $26.38 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $26.47 | $37.27 | $58.8 | $33.11 |
| Short term investments | ||||
| Net receivables | $0.89 | $0.72 | $0.56 | |
| Inventory | ||||
| Total current assets | $29.09 | $40.18 | $59.32 | $34.02 |
| Long term investments | ||||
| Property, plant & equipment | $2.12 | $0.62 | $0.93 | $1.09 |
| Goodwill & intangible assets | $19.09 | $19.09 | ||
| Total noncurrent assets | $2.17 | $0.66 | $20.07 | $20.23 |
| Total investments | ||||
| Total assets | $31.26 | $40.84 | $79.39 | $54.24 |
| Current liabilities | ||||
| Accounts payable | $3.02 | $0.61 | $1.3 | $1.08 |
| Deferred revenue | ||||
| Short long term debt | $0.24 | $0.24 | $0.24 | $0.22 |
| Total current liabilities | $3.26 | $1.22 | $1.54 | $1.36 |
| Long term debt | $1.61 | $0.06 | $0.3 | $0.38 |
| Total noncurrent liabilities | $1.61 | $0.06 | $0.3 | $0.38 |
| Total debt | $1.85 | $0.3 | $0.53 | $0.6 |
| Total liabilities | $4.88 | $1.27 | $1.84 | $1.74 |
| Shareholders' equity | ||||
| Retained earnings | -$315.91 | -$297.93 | -$259.09 | -$244.91 |
| Other shareholder equity | ||||
| Total shareholder equity | $26.38 | $39.57 | $77.55 | $52.51 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $4.31 | $2.95 | $4.27 | |
| Selling, general & administrative | $1.14 | $1.21 | $1.4 | |
| Total operating expenses | $5.04 | $5.45 | $4.16 | $4.67 |
| Operating income | -$5.45 | -$4.16 | -$4.67 | |
| Income from continuing operations | ||||
| EBIT | -$5.34 | -$3.74 | -$4.28 | |
| Income tax expense | ||||
| Interest expense | $0.1 | $0.22 | $0.18 | |
| Net income | ||||
| Net income | -$4.94 | -$5.34 | -$3.96 | -$4.46 |
| Income (for common shares) | -$5.34 | -$3.96 | -$4.46 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.01 | |||
| Cost of revenue | ||||
| Gross Profit | $2.01 | |||
| Operating activities | ||||
| Research & development | $15.17 | $12.39 | $8.79 | $6.31 |
| Selling, general & administrative | $5.99 | $5.75 | $5.43 | $5.29 |
| Total operating expenses | $18.56 | $38.83 | $14.22 | $11.6 |
| Operating income | -$18.56 | -$38.83 | -$14.22 | -$9.59 |
| Income from continuing operations | ||||
| EBIT | -$17.34 | -$38.84 | -$14.18 | -$9.64 |
| Income tax expense | ||||
| Interest expense | $0.64 | $0 | $0 | $0.01 |
| Net income | ||||
| Net income | -$17.98 | -$38.84 | -$14.19 | -$9.65 |
| Income (for common shares) | -$17.98 | -$38.84 | -$14.19 | -$9.65 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$5.34 | -$3.96 | -$4.46 | |
| Operating activities | ||||
| Depreciation | $0.03 | $0.04 | -$0.12 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.15 | $0.16 | $0.16 | |
| Total cash flows from operations | -$3.7 | -$4.5 | -$3.33 | |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.06 | ||
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.01 | -$0.06 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$13.33 | -$3.7 | -$4.51 | -$3.38 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$17.98 | -$38.84 | -$14.19 | -$9.65 |
| Operating activities | ||||
| Depreciation | $0.19 | $0.18 | $0.38 | $0.34 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.8 | $0.85 | $0.72 | $0.66 |
| Total cash flows from operations | -$14.67 | -$21.43 | -$12.72 | -$9.83 |
| Investing activities | ||||
| Capital expenditures | -$0.12 | -$0.07 | -$0.05 | -$0.24 |
| Investments | ||||
| Total cash flows from investing | -$0.12 | -$0.07 | -$0.05 | -$0.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4 | $38.51 | $35.78 | |
| Net borrowings | -$0.01 | -$0.03 | -$0.04 | -$0.12 |
| Total cash flows from financing | $3.99 | -$0.03 | $38.47 | $35.66 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$10.79 | -$21.54 | $25.7 | $25.59 |
News
Fundamentals
| Market cap | $10.07M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 10.17M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$18.70M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.54 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.84 |
|---|---|
| ROA | -78.24% |
| ROE | N/A |
| Debt/Equity | 0.18 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.32 |
| Quick ratio | N/A |